{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:25:33Z","timestamp":1787646333883,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"The Welch Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jbc.2026.111476","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:12:15Z","timestamp":1776467535000},"page":"111476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects"],"prefix":"10.1016","volume":"302","author":[{"given":"Samuel A.","family":"Blackman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlam N.","family":"Qerqez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison G.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole V.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5744-787X","authenticated-orcid":false,"given":"Justin M.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace S.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Aldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-7920","authenticated-orcid":false,"given":"Kayla G.","family":"Sprenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-5686","authenticated-orcid":false,"given":"Jangsoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Verrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-1517","authenticated-orcid":false,"given":"Martin J.","family":"Stoddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1268-7164","authenticated-orcid":false,"given":"Annalee W.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-8486","authenticated-orcid":false,"given":"Jennifer A.","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.111476_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2026.111476_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jbc.2026.111476_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2026.111476_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","article-title":"The impact of VEGF on cancer metastasis and systemic disease","volume":"86","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.jbc.2026.111476_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12680","article-title":"Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism","volume":"7","author":"Yang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.111476_bib6","first-page":"16","article-title":"Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis","volume":"31","author":"Xu","year":"2012","journal-title":"J. Exp. Clin. Cancer Res. CR."},{"key":"10.1016\/j.jbc.2026.111476_bib7","first-page":"14","article-title":"Angiogenesis in cancer: anti-VEGF escape mechanisms","volume":"1","author":"Prager","year":"2012","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.jbc.2026.111476_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3389\/fcell.2020.00584","article-title":"Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs","volume":"8","author":"Montemagno","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jbc.2026.111476_bib9","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","article-title":"Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer","volume":"49","author":"Rougier","year":"2013","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.jbc.2026.111476_bib10","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1038\/s41467-022-33991-6","article-title":"PD-L1-directed PlGF\/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.111476_bib11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1517\/14728222.2014.948420","article-title":"Placental growth factor in cancer","volume":"18","author":"Dewerchin","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jbc.2026.111476_bib12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1078-0432.CCR-19-1985","article-title":"Impact of prior bevacizumab treatment on VEGF-A and PlGF levels and outcome following second-line aflibercept treatment: biomarker post hoc analysis of the VELOUR trial","volume":"26","author":"Van Cutsem","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2026.111476_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.jbc.2026.111476_bib14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","article-title":"Anti-PlGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels","volume":"131","author":"Fischer","year":"2007","journal-title":"Cell."},{"key":"10.1016\/j.jbc.2026.111476_bib15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cell.2010.01.033","article-title":"PlGF blockade does not inhibit angiogenesis during primary tumor growth","volume":"141","author":"Bais","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2026.111476_bib16","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1073\/pnas.1109029108","article-title":"Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy","volume":"108","author":"Yao","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.111476_bib17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.cell.2013.01.036","article-title":"Targeting placental growth factor\/neuropilin 1 pathway inhibits growth and spread of medulloblastoma","volume":"152","author":"Snuderl","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2026.111476_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cell.2010.02.039","article-title":"Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease","volume":"141","author":"Van de Veire","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2026.111476_bib19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s43018-025-00957-8","article-title":"The curated cancer cell atlas provides a comprehensive characterization of tumors at single-cell resolution","volume":"6","author":"Tyler","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.jbc.2026.111476_bib20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1074\/jbc.M508199200","article-title":"Cross-species vascular endothelial growth factor (VEGF)-Blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF","volume":"281","author":"Liang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.111476_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002614","article-title":"Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing","volume":"3","author":"Martino","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jbc.2026.111476_bib22","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.1616408114","article-title":"Biophysical properties of the clinical-stage antibody landscape","volume":"114","author":"Jain","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.111476_bib23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nprot.2008.48","article-title":"A protocol for determination of anticardiolipin antibodies by ELISA","volume":"3","author":"Pierangeli","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jbc.2026.111476_bib24","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1074\/jbc.M507783200","article-title":"Structure-function studies of two synthetic anti-vascular endothelial growth factor fabs and comparison with the Avastin Fab","volume":"281","author":"Fuh","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.111476_bib25","doi-asserted-by":"crossref","first-page":"24818","DOI":"10.1074\/jbc.M200730200","article-title":"Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth Factor-2, and heparin via its b1b2 domain","volume":"277","author":"Mamluk","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.111476_bib26","doi-asserted-by":"crossref","DOI":"10.3791\/51312-v","article-title":"Endothelial cell tube Formation assay for the in vitro study of angiogenesis","author":"DeCicco-Skinner","year":"2014","journal-title":"J. Vis. Exp. Jove"},{"key":"10.1016\/j.jbc.2026.111476_bib27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10637-014-0129-y","article-title":"Effects of the combination of TRC105 and bevacizumab on endothelial cell biology","volume":"32","author":"Liu","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jbc.2026.111476_bib28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/micc.12113","article-title":"Placenta growth factor and vascular endothelial growth Factor-A have differential, cell-type specific atterns of expression in vascular cells","volume":"21","author":"Xiang","year":"2014","journal-title":"Microcirculation"},{"key":"10.1016\/j.jbc.2026.111476_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0006-291X(02)00677-0","article-title":"Loss of placental growth factor protects mice against vascular permeability in pathological conditions","volume":"295","author":"Luttun","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2026.111476_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67289-8","article-title":"Angiogenesis analyzer for ImageJ \u2014 a comparative morphometric analysis of \u201cEndothelial Tube Formation Assay\u201d and \u201cFibrin Bead Assay.\u201d","volume":"10","author":"Carpentier","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2026.111476_bib31","first-page":"531","article-title":"Inhibition of placental growth factor in renal cell carcinoma","volume":"35","author":"Bessho","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbc.2026.111476_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040186","article-title":"Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1\/FLT1","volume":"4","author":"Lee","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.jbc.2026.111476_bib33","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.3390\/ijms24097792","article-title":"Neuropilin-1 knockout and rescue confirms its role to promote metastasis in MDA-MB-231 breast cancer cells","volume":"24","author":"Al-Zeheimi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2026.111476_bib34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3892\/ijo.2015.3082","article-title":"Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer","volume":"47","author":"Devery","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbc.2026.111476_bib35","first-page":"2683","article-title":"Heterogeneity of vascular endothelial growth factor receptors 1, 2, 3 in primary human colorectal carcinoma","volume":"36","author":"Nasir","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbc.2026.111476_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.01.010","article-title":"VEGF\/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-\u03baB and \u03b2-catenin","volume":"373","author":"Luo","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbc.2026.111476_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028947","article-title":"Phosphorylation of Akt and ERK1\/2 is required for VEGF-A\/VEGFR2-Induced proliferation and migration of lymphatic endothelium","volume":"6","author":"Dellinger","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.111476_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111722","article-title":"Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects","volume":"28","author":"Zhong","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.jbc.2026.111476_bib39","doi-asserted-by":"crossref","first-page":"28045","DOI":"10.1074\/jbc.M700319200","article-title":"Molecular mapping and functional characterization of the VEGF164 heparin-binding domain","volume":"282","author":"Krilleke","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.111476_bib40","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1021\/bi101662j","article-title":"Binding of a C-end rule peptide to neuropilin-1 receptor: a molecular modeling approach","volume":"50","author":"Haspel","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.jbc.2026.111476_bib41","doi-asserted-by":"crossref","first-page":"11082","DOI":"10.1074\/jbc.M111.331140","article-title":"Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1","volume":"287","author":"Parker","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.111476_bib42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/19420862.2014.985132","article-title":"Five birds, one stone: neutralization of \u03b1-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody","volume":"7","author":"Rouha","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.jbc.2026.111476_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101067","article-title":"Recombinant antibodies recognize conformation-dependent epitopes of the leucine zipper of misfolding-prone myocilin","volume":"297","author":"Patterson-Orazem","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.111476_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(96)00208-6","article-title":"Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system","volume":"201","author":"Krebber","year":"1997","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jbc.2026.111476_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0022-1759(03)00100-5","article-title":"Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis","volume":"276","author":"Hayhurst","year":"2003","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jbc.2026.111476_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad0966","article-title":"A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough","volume":"7","author":"Nguyen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jbc.2026.111476_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14573-9","article-title":"Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus","volume":"7","author":"Choijilsuren","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2026.111476_bib48","doi-asserted-by":"crossref","first-page":"11111","DOI":"10.1073\/pnas.96.20.11111","article-title":"Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo","volume":"96","author":"Lovich","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.111476_bib49","doi-asserted-by":"crossref","first-page":"34796","DOI":"10.1074\/jbc.M806692200","article-title":"A catalytic role of heparin within the extracellular matrix","volume":"283","author":"Mitsi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2026.111476_bib50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2014.03.015","article-title":"A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?","volume":"60","author":"Ohlin","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jbc.2026.111476_bib51","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1074\/jbc.M114.585281","article-title":"The Bordetella adenylate cyclase repeat-in-toxin (RTX) Domain is immunodominant and elicits neutralizing antibodies","volume":"290","author":"Wang","year":"2015","journal-title":"J. Biol. Chem."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826003480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826003480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:33:36Z","timestamp":1787643216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826003480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0021925826003480"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.111476","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.10.25.684565","asserted-by":"object"}]},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.111476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"111476"}}